Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure
Dive into the most pressing topics impacting the biopharma industry on Denatured.
This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bias, data challenges, data management plans, and human expertise.
Paul Agapow, Director of Innovation, Data Science and Strategy, GlaxoSmithKline
Mike King, Senior Director of Product and Strategy, IQVIA
Nindhana Paranthaman, Executive Medical Director, Exelixis
Moritz von Stosch, Chief Information Officer, DataHow
Lori Ellis, Head of Insights, BioSpace
Lori Ellis is the head of insights at BioSpace, providing industry analysis as well as custom content for BioSpace clients. Her current focus is on the ever-evolving impact of technology on the pharmaceutical industry. You can reach her at email@example.com. Follow her on LinkedIn.
Also available on Apple podcasts